CompletedPhase 2NCT00023426
TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis
Studying Tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centers for Disease Control and Prevention
- Principal Investigator
- Naomi Bock, MDCenters for Disease Control & Prevention
- Intervention
- rifapentine(drug)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1999 – 2003
Study locations (23)
- Central Arkansas Veterans Health System, Little Rock, Arkansas, United States
- LA County/USC Medical Center, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Denver Department of Public Health and Hospitals, Denver, Colorado, United States
- Washington, D.C. VAMC, Washington D.C., District of Columbia, United States
- Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
- Hines VA Medical Center, Hines, Illinois, United States
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Boston Medical Center, Boston, Massachusetts, United States
- New Jersey Medical School, Newark, New Jersey, United States
- New York University School of Medicine, New York, New York, United States
- Columbia University/Presbyterian Medical Center, New York, New York, United States
- Harlem Hospital Center, New York, New York, United States
- Carolinas Medical Center, Charlotte, North Carolina, United States
- Duke University Medical Center, Durham, North Carolina, United States
- +8 more locations on ClinicalTrials.gov
Collaborators
US Department of Veterans Affairs
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00023426 on ClinicalTrials.govOther trials for Tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07164742Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)Johns Hopkins University
- RECRUITINGNCT0707721318F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis PatientsChildren's Hospital Medical Center, Cincinnati
- RECRUITINGNCT07451899TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung DiseaseUniversitas Padjadjaran
- RECRUITINGNCT06845618Blood Tuberculosis DNA Levels to Monitor Tuberculosis TreatmentUniversity of Oxford
- ENROLLING BY INVITATIONNANCT06984887Evaluation of New TB Diagnostic Tests (NATs) in PakistanMercy Corps Pakistan
- RECRUITINGNCT07018076Candidate Clinical Correlate of Prognostic Outcome for TB StudyUniversity of California, San Francisco
- RECRUITINGNANCT07271225Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and VomitingIndonesia University
- RECRUITINGNCT06585358DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary TuberculosisKarolinska Institutet